WT1 peptide cancer vaccine composition for transdermal administration

Patent metadata

Field	Value
Publication number	US-10449144-B2
Application number	US-201414166932-A
Country	US
Kind code	B2
Filing date	Jan 29, 2014
Priority date	Feb 5, 2013
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.

First claim

What is claimed is:

1. A method for inducing cellular immunity in a subject, which comprises:
transdermally administering to the subject, under a mildly irritating condition, a cancer vaccine composition comprising:
(i) a WT1 peptide and/or a modified WT1 peptide;
(ii) a cyclooxygenase inhibitor; and
(iii) at least one helper peptide and/or modified helper peptide.

2. The method according to claim 1 , wherein the method is for treating a cancer in the subject.

3. The method according to claim 1 , wherein the mildly irritating condition is a condition under which transepidermal water loss (TEWL) in a model animal for skin irritation evaluation before administration of the composition is 50 g/h·m 2 or less.

4. The method according to claim 1 , wherein the mildly irritating condition is a condition under which the cutaneous TSLP level in a model animal for skin irritation evaluation at completion of administration of the composition is 10000 pg/mg protein or less.

5. The method according to claim 1 , wherein the helper peptide and/or modified helper peptide is/or is modified from tubercle bacillus -derived helper peptide, measles virus-derived helper peptide, hepatitis B virus-derived helper peptide, hepatitis C virus-derived helper peptide, Chlamydia trachomatis -derived helper peptide, Plasmodium falciparum sporozoite-derived helper peptide, keyhole limpet haemocyanin-derived helper peptide, tetanus toxin-derived helper peptide, universal helper analog, or a cancer cell-derived helper peptide, excepting a WT1-derived helper peptide.

6. The method according to claim 5 , wherein the cancer cell-derived helper peptide and/or modified helper peptide is IMA-MMP-001 helper peptide, CEA-006 helper peptide, MMP-001 helper peptide, TGFBI-004 helper peptide, HER-2/neu aa776-790 helper peptide, AE36 helper peptide, AE37 helper peptide, MET-005 helper peptide, or BIR-002 helper peptide.

7. The method according to claim 1 , wherein the helper peptide and/or modified helper peptide is/or is modified from pertussis toxin-derived helper peptide or diphtheria toxin-derived helper peptide.

8. The method according to claim 1 , wherein the helper peptide and/or modified helper peptide is peptide-25, or peptide-25B.

9. The method according to claim 1 , wherein the vaccine composition further comprises a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof, wherein the pharmacologically acceptable acid is selected from the group consisting of myristic acid, isostearic acid, decanoic acid, lauric acid, oleic acid, and malic acid.

10. The method according to claim 1 , wherein the cancer vaccine composition further comprises imiquimod.

11. The method according to claim 10 , wherein the cyclooxygenase inhibitor is selected from loxoprofen, etodolac, indomethacin, aspirin, diclofenac, ketoprofen, celecoxib, and valdecoxib.

12. The method according to claim 11 , wherein the cyclooxygenase inhibitor is selected from loxoprofen, etodolac, diclofenac, celecoxib, and valdecoxib.

13. The method according to claim 12 , wherein the vaccine composition further comprises a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof, wherein the pharmacologically acceptable acid is selected from myristic acid, isostearic acid, decanoic acid, lauric acid, oleic acid, and malic acid.

14. The method according to claim 1 , wherein the cyclooxygenase inhibitor is selected from loxoprofen, etodolac, indomethacin, aspirin, diclofenac, ketoprofen, celecoxib, and valdecoxib.

15. The method according to claim 14 , wherein the cyclooxygenase inhibitor is selected from loxoprofen, etodolac, diclofenac, celecoxib, and valdecoxib.

16. The method according to claim 15 , wherein the vaccine composition further comprises a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof, wherein the pharmacologically acceptable acid is selected from myristic acid, isostearic acid, decanoic acid, lauric acid, oleic acid, and malic acid.

17. The method according to claim 14 , wherein the vaccine composition further comprises a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof, wherein the pharmacologically acceptable acid or the pharmacologically acceptable salt is selected from myristic acid or isostearic acid and the helper peptide is peptide-25.

18. The method according to claim 15 , wherein the helper peptide is peptide-25.

Assignees

• Nitto Denko Corp
• Univ Osaka

Inventors

• Okubo Katsuyuki
• Maeda Yoshiki
• Okazaki Arimichi
• Asari Daisuke
• Shishido takuya
• Hori Mitsuhiko
• Sugiyama Haruo

Classifications

• A61K2039/80

  Vaccine for a specifically defined cancer · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title